Latest news with #Hutchmed
South China Morning Post
14-04-2025
- Business
- South China Morning Post
Hutchmed weighs cancer drug's supply-chain options amid US-China trade war
Hutchmed (China) is evaluating supply-chain options for a blood-cancer drug recently approved by Beijing to mitigate impact from the ongoing US-China trade war, according to its chief. Advertisement Last month the company won conditional nationwide approval from China's National Medical Products Administration (NMPA) to sell tazemetostat, after it completed a phase two bridging study involving 42 patients. The approval is for follicular-lymphoma patients whose cancer has a mutation called EZH2 and who either failed to respond to treatment or whose cancer has recurred after therapy. The mutation exists in 20 to 25 per cent of Chinese patients with the cancer, Hutchmed CEO and chief scientific officer Su Weiguo said. In 2022, new follicular lymphoma cases totalled 78,000 in the US and 81,000 in China, according to Hutchmed. Tazemetostat is the first EZH2 inhibitor approved by the NMPA, Su said. Hutchmed aims to conduct separate trials in China to potentially expand the drug's usage to patients with solid cancers. 'In recent years, drugs to inhibit EZH2 have been studied globally for treating multiple solid tumours such as triple-negative breast, ovarian and prostate cancers,' he said. 'We plan to kick off similar studies on tazemetostat among Chinese patients with solid tumours.' Advertisement Tazemetostat is currently manufactured in the US and is likely to be subject to tariffs when imported into China, so Hutchmed is evaluating options to minimise the cost impact.
Yahoo
14-02-2025
- Business
- Yahoo
Hutchmed price target raised to $27 from $26 at BofA
BofA raised the firm's price target on Hutchmed (HCM) to $27 from $26 and keeps a Buy rating on the shares. While noting it sees 'some regulatory headwinds potentially ahead,' the firm keeps a Buy rating on the shares and cites higher revenue expectations for key assets after 'strong performance in 2024' for its revised price target Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions. Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on HCM: Hutchmed announces NMPA approval for Orpathys supplemental new drug application Hutchmed price target lowered to $26 from $30 at BofA Morning Movers: Neumora Therapeutics plummets after KOASTAL-1 misses endpoint Hutchmed announces NDA acceptance in China, payment from AstraZeneca Hutchmed divests 45% interest in Shanghai Hutchison for $608M Sign in to access your portfolio
